Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
The collaboration will support Canada with direct access to rapid pandemic response capabilities
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month
This work has been published in the journal ‘ACS applied materials and interface’
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
This robust growth has come despite the raging pandemic for most part of the quarter
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Subscribe To Our Newsletter & Stay Updated
